Based on the sequencing of 101 ccRCC tumours (TRACERx consortium), Turajlic et al. showed VHL mutations to be a consistent clonal event found in main tumours (77/106), which is consistent with the low impact of the mutational status of VHL to guide therapies [37]. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.